1. Executive Summary
2. Introduction to Biotechnology
2.1 Background to Biotech Drugs
2.1.1 Commonly-Used Terminology
2.1.2 Summary of Recombinant DNA Technology
2.1.3 Classes of Biotech Drugs
2.2 Biotech Drugs are Gaining Increasing Importance
2.2.1 Biopharmaceuticals are Versatile Agents
3. The World Biotech Market Analysis & Forecast 2008 & 2023
3.1 World Biotech Market Expanding Rapidly
3.2 Biotech Market Revenues Grew Significantly in 2007
3.3 Biotech Market Revenues Forecast 2008-2023
3.4 The World Biotech Market is Dominated by North America
3.5 Big Pharma Generates Strong Biotech Drug Revenues in 2007
3.6 Amgen Records Largest Sales in the Global Biotech Industry in 2007
4. Market Drivers and Restraints in the Global Biotech Market
4.1 SWOT Analysis for the Biotech Market
4.2 The Principal Drivers in the Biotech Market
4.3 The Principal Restraints in the Biotech Market
4.4 The Benefits of Biotechnology-Based Products
4.5 Biotech Industry Market Capitalisation Gains Momentum
4.6 Landmark Biotech Financing in 2007
4.7 Healthcare Biotech Venture Capitalist Deals in 2007
4.8 Healthcare Biotech VC Fund Investments
4.9 Healthcare Biotech IPOs Funds in 2007
4.10 New Technology Platforms in Biotech R&D
4.10.1 The Application of Genomic Technology in R&D
4.10.2 Leading Genomics Companies Benefit Through Lucrative Deals with Biotech and Big Pharma
4.10.3 The Application of Proteomics in Drug Discovery Widens
4.11 Pharmacogenomics is Crucial to Biotech Revenue Prospects
4.11.1 Pharmacogenomics Holds Potential Benefits
4.11.2 Biomarkers Add to Biotech Technology
4.12 US-Style Advance Technology Platform (ATP)
4.13 Collaborative Deals That Foster Genomic Applications
4.14 Rapidly Expanding Biotech Market Has Marked Challenges Ahead
4.15 Increasing Use of Pharmacoeconomic Evaluations is Having an Impact on Revenues of Biotech Medicines
4.16 Biotech Companies Must Improve Safety Profile of Drugs
4.17 Lack of Adequate Reimbursement Will Impede Potential Growth of the Biotech Market
4.18 Potential Growth in Biogenerics (Biosimilars) Market Will Hamper Revenues of Branded Biotech Drugs
4.19 EU Leads the Way in Biogenerics Market
4.20 The US Awaits New Biogenerics Regulatory Framework
4.21 US Congressional Budget Office (CBO) Estimates Biogenerics Will Help Reduce Drug Bills in the Long-Term
4.22 Biogenerics Manufacturers Will Face Several Hurdles Despite Lucrative Prospects
4.23 European Drug Regulation Framework Promises Increasing Entry of Biogenerics
4.24 European Medicines Agency (EMEA) Amends its Biogeneric Regulation
4.25 The Future of Healthcare Biotech looks Promising
5. Top-10 Biotech Companies Forecast & Analyses 2008-2023
5.1 Top-10 Biotech Companies Revenue Trends Looking Forward
6. Amgen
6.1 Key Therapeutic Areas
6.1.1 Cancer
6.1.2 Inflammation
6.1.3 Neurology
6 1.4 Metabolic Disorders
6.1.5 Haematology
6.2 Amgen Key Financials
6.3 Amgen Revenue Forecast 2008-2023
6.4 Amgen's Leading Drugs
6.4.1 Amgen's Leading Drug Sales, 2007
6.5 Amgen's Geographical Sales
6.6 Amgen's Top-Three Drugs - Sales Forecasts 2008-2013
6.7 Amgen’s Phase III Pipeline
7. Genentech
7.1 Key Therapeutic Areas
7.2 Genentech Key Financials
7.3 Genentech Revenue Forecast 2008-2023
7.4 Genentech’s Leading Drugs
7.5 Genentech's Geographical Sales
7.6 Genentech’s Top-Three Drugs - Sales Forecasts 2008-2013
7.7 Genentech’s Phase III Pipeline
8. UCB
8.1 Key Therapeutic Areas
8.2 UCB Key Financials
8.3 UCB Revenue Forecast 2008-2023
8.4 UCB's Leading Drugs
8.4.1 UCB's Leading Drugs Sales, 2007
8.5 UCB's Geographical Sales
8.6 UCB's Top-Three Drugs - Sales Forecasts 2008-2013
8.7 UCB's Phase III Pipeline
9. Gilead Sciences
9.1 Key Therapeutic Areas
9.2 Gilead Sciences Key Financials
9.3 Gilead Sciences Revenue Forecast 2008-2023
9.4 Gilead Sciences' Leading Drugs
9.5 Gilead Sciences Geographic Sales
9.6 Gilead Sciences' Top-Three Drugs - Sales Forecasts 2008-2013
9.7 Gilead Sciences’ Phase III Pipeline
10. Genzyme
10.1 Key Therapeutic Areas
10.2 Genzyme Key Financials
10.3 Genzyme Revenue Forecast 2008-2023
10.4 Genzyme's Leading Drugs
10.5 Genzyme's Geographical Sales
10.6 Genzyme's Top-Three Drugs - Total Sales Forecasts 2008-2013
10.7 Genzyme’s Phase III Pipeline
11. Biogen Idec
11.1 Key Therapeutic Areas
11.2 Biogen Idec Key Financials
11.3 Biogen Idec Revenue Forecast 2008-2023
11.4 Biogen Idec's Leading Drugs
11.5 Biogen Idec's Geographical Sales
11.6 Biogen Idec's Top-Two Drugs - Sales Forecasts 2008-2013
11.7 Biogen Idec's Phase III Pipeline
12. CSL
12.1 Key Therapeutic Areas
12.2 CSL Key Financials
12.3 CSL Revenue Forecast 2008-2023
12.4 CSL's Leading Drugs
12.5 CSL's Geographical Sales
12.6 CSL's Top-Three Drugs - Sales Forecasts 2008-2013
12.7 CSL's Phase III Pipeline
13. Cephalon
13.1 Key Therapeutic Areas
13.2 Cephalon Key Financials
13.3 Cephalon's Revenue Forecast 2008-2023
13.4 Cephalon's Leading Drugs
13.5 Cephalon's Geographical Sales
13.6 Cephalon's Top -Three Drugs - Sales Forecasts 2008-2013
13.7 Cephalon's Phase III Pipeline
14. Celgene
14.1 Key Therapeutic Areas
14.2 Celgene Key Financials
14.3 Celgene Revenue Forecast 2008-2023
14.4 Celgene's Leading Drugs
14.5 Celgene's Geographical Sales
14.6 Celgene's Top-Three Drugs - Sales Forecasts 2008-2013
14.7 Celgene's Phase III Pipeline
15. Actelion
15.1 Key Therapeutic Areas
15.2 Actelion Key Financials
15.3 Actelion Revenue Forecast 2008-2023
15.4 Actelion's Leading Drugs
15.5 Actelion's Geographical Sales
15.6 Actelion's Top-Three Drugs - Sales Forecasts 2008-2013
15.7 Actelion's Phase III Pipeline
16. Conclusions
16.1 Biopharmaceutical Treatment Options Expand Significantly over Past Two Decades
16.2 Biotech Industry Market Capitalisation Increases
16.3 Biotech Market Generated Significant Revenues in 2007
16.4 Overall Global Biotech Sales Prospects During the Forecast Period
16.5 Prospects for the Top-10 Biotech Companies
16.6 Big Pharma’s Presence in the Biotech Arena
16.7 Potential Growth in the Biogenerics Market
16.8 The US Awaits Consolidation of Biogenerics Regulatory Framework
16.9 Prospects for the Healthcare Biotech Market Leaders
List of Tables
Table 3.1 Global Biotech Market Revenues ($m) Forecast 2008-2023
Table 3.2 Global Market Share (%) and Revenue ($m) by Country/Region, 2007
Table 3.3 Big Pharma’s Biotech Revenue ($m), 2007
Table 3.4 Top-10 Biotech Companies ($m), 2007
Table 4.1 Biotech Market SWOT Analysis
Table 4.2 Biotech Market Capitalisation ($bn) over 10-Year Period, 1997-2007
Table 4.3 Patent Expiration of Leading Biotech Drugs
Table 5.1 Top-10 Biotech Companies Revenues ($m) Forecast, 2008-2023
Table 6.1 Amgen Revenues and Net Income ($m), 2003-2007
Table 6.2 Amgen: Total Corporate Revenues ($m), 2008-2023
Table 6.3 Amgen Leading Drug Sales ($m), 2007
Table 6.4 Amgen's Geographical Sales ($m), 2007
Table 6.5 Amgen's Top-Three Drugs - Sales ($m) Forecast, 2008-2013
Table 6.6 Amgen's Phase III Pipeline, 2008
Table 7.1 Genentech Revenues and Net Income ($m), 2003-2007
Table 7.2 Genentech: Total Corporate Revenues ($m), 2008-2023
Table 7.3 Genentech's Leading Drugs ($m), 2007
Table 7.4 Genentech’s Geographical Sales ($m), 2007
Table 7.5 Genentech’s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 7.6 Genentech's Phase III Pipeline, 2008
Table 8.1 UCB Revenues and Net Profit ($m), 2003-2007
Table 8.2 UCB: Total Corporate Revenues ($m), 2008-2023
Table 8.3 UCB's Leading Drugs ($m), 2007
Table 8.4 UCB’s Geographical Sales ($m), 2007
Table 8.5 UCB's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 8.6 UCB's Phase III Pipeline, 2008
Table 9.1 Gilead Sciences Revenues ($m), 2003-2007
Table 9.2 Gilead Sciences: Total Corporate Revenues ($m), 2008-2023
Table 9.3 Gilead Sciences' Leading Drugs Sales ($m), 2006-2007
Table 9.4 Gilead Sciences' Geographical Sales ($m), 2007
Table 9.5 Gilead Sciences’ Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 9.6 Gilead Sciences' Phase III Pipeline, 2008
Table 10.1Genzyme Revenues ($m), 2003-2007
Table 10.2 Genzyme: Total Corporate Revenues ($m), 2008-2023
Table 10.3 Genzyme's Leading Products ($m), 2006-2007
Table 10.4 Genzyme's Geographical Sales ($m), 2006
Table 10.5 Genzyme's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 10.6 Genzyme's Phase III Pipeline, 2008
Table 11.1 Biogen Idec Revenues ($m), 2003-2007
Table 11.2 Biogen Idec: Total Corporate Revenues ($m), 2008-2023
Table 11.3 Biogen Idec's Leading Drugs ($m), 2006-2007
Table 11.4 Biogen Idec's Geographical Sales ($m), 2006-2007
Table 11.5 Biogen Idec's Top-Two Drugs - Total Sales ($m) Forecast, 2008-2013
Table 11.6 Biogen Idec’s Phase III Pipeline, 2008
Table 12.1 CSL Revenues and Net Profit ($m), 2003-2007
Table 12.2 CSL: Total Corporate Revenues ($m), 2008-2023
Table 12.3 CSL's Leading Drugs ($m), 2006-2007
Table 12.4 CSL's Geographical Sales ($m), 2007
Table 12.5 CSL's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 12.6 CSL’s Phase III Pipeline, 2008
Table 13.1 Cephalon's Revenues ($m), 2003-2007
Table 13.2 Cephalon: Total Corporate Revenues ($m), 2008-2023
Table 13.3 Cephalon's Leading Drugs ($m), 2006-2007
Table 13.4 Cephalon's Geographical Sales ($m), 2007
Table 13.5 Cephalon's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 13.6 Cephalon's Phase III Pipeline, 2008
Table 14.1 Celgene's Revenues ($m), 2003-2007
Table 14.2 Celgene: Total Corporate Revenues ($m), 2008-2023
Table 14.3 Celgene's Leading Drugs ($m), 2006-2007
Table 14.4 Celgene's Geographical Sales ($m), 2006-2007
Table 14.5 Celgene's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 14.6 Celgene's Phase III Pipeline, 2008
Table 15.1 Actelion Revenues and Net Profit ($m), 2003-2007
Table 15.2 Actelion: Total Corporate Revenues ($m), 2008-2023
Table 15.3 Actelion's Leading Drugs ($m), 2006-2007
Table 15.4 Actelion's Geographical Sales ($m), 2006-2007
Table 15.5 Actelion's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Table 15.6 Actelion’s Phase III Pipeline, 2008
List of Figures
Figure 3.1 Global Biotech Market Revenues ($m) Forecast 2008-2023
Figure 3.2 Global Biotech Market Share (%), 2007
Figure 3.3 Big Pharma Biotech Market Share (%), 2007
Figure 3.4 Top-10 Biotech Companies Market Share (%), 2007
Figure 4.1 Biotech Market Capitalisation ($bn) over 10-Year Period 1997-2007
Figure 5.1 Top-10 Biotech Market Revenues ($m) Forecast, 2008-2023
Figure 6.1 Amgen Revenues ($m), 2003-2007
Figure 6.2 Amgen Net Income ($m), 2003-2007
Figure 6.3 Amgen: Total Corporate Revenues ($m), 2008-2023
Figure 6.4 Amgen’s Leading Drugs: Contribution to Company Sales (%), 2007
Figure 6.5 Amgen's Geographical Sales (%), 2007
Figure 6.6 Amgen's Top-Three Drugs – Total Sales ($m) Forecast, 2008-2013
Figure 7.1 Genentech Revenues ($m), 2003-2007
Figure 7.2 Genentech Net Income ($m), 2003-2007
Figure 7.3 Genentech: Total Corporate Revenues ($m), 2008-2023
Figure 7.4 Genentech's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 7.5 Genentech’s Geographical Sales (%), 2007
Figure 7.6 Genentech’s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 8.1 UCB Revenues ($m), 2003-2007
Figure 8.2 UCB Net Profit ($m), 2003-2007
Figure 8.3 UCB: Total Corporate Revenues ($m), 2008-2023
Figure 8.4 UCB's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 8.5 UCB's Geographical Sales (%), 2007
Figure 8.6 UCB's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 9.1 Gilead Sciences Revenues ($m), 2003-2007
Figure 9.2 Gilead Sciences: Total Corporate Revenues ($m), 2008-2023
Figure 9.3 Gilead Sciences' Leading Drugs: Contribution to Company Sales (%), 2007
Figure 9.4 Gilead Sciences' Geographical Sales (%), 2007
Figure 9.5 Gilead Sciences' Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 10.1 Genzyme Revenues ($m), 2003-2007
Figure 10.2 Genzyme: Total Corporate Revenues ($m), 2008-2023
Figure 10.3 Genzyme's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 10.4 Genzyme Geographical Sales (%), 2006
Figure 10.5 Genzyme's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 11.1 Biogen Idec Revenues ($m), 2003-2007
Figure 11.2 Biogen Idec: Total Corporate Revenues ($m), 2008-2023
Figure 11.3 Biogen Idec's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 11.4 Biogen Idec's Geographical Sales (%), 2007
Figure 11.5 Biogen Idec's Top-Two Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 12.1 CSL Revenues ($m), 2003-2007
Figure 12.2 CSL Net Profit ($m), 2003-2007
Figure 12.3 CSL: Total Corporate Revenues ($m), 2008-2023
Figure 12.4 CSL's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 12.5 CSL's Geographical Sales (%), 2007
Figure 12.6 CSL's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 13.1 Cephalon's Revenues ($m), 2003-2007
Figure 13.2 Cephalon: Total Corporate Revenues ($m), 2008-2023
Figure 13.3 Cephalon's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 13.4 Cephalon's Geographical Sales (%), 2007
Figure 13.5 Cephalon's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 14.1 Celgene's Revenues ($m), 2003-2007
Figure 14.2 Celgene: Total Corporate Revenues ($m), 2008-2023
Figure 14.3 Celgene's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 14.4 Celgene's Geographical Sales (%), 2007
Figure 14.5 Celgene's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
Figure 15.1 Actelion Revenues ($m), 2003-2007
Figure 15.2 Actelion Net Profit ($m), 2003-2007
Figure 15.3 Actelion: Total Corporate Revenues ($m), 2008-2023
Figure 15.4 Actelion's Leading Drugs: Contribution to Company Sales (%), 2007
Figure 15.5 Actelion's Geographical Sales (%), 2007
Figure 15.6 Actelion's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013